title: Cardiopulmonary arrest after severe anaphylactic reaction to second infusion of infliximab in a patient with ankylosing spondylitis.
authors.forename: Haruka
authors.initials: H
authors.lastname: Miki
authors.forename: Akiko
authors.initials: A
authors.lastname: Okamoto
authors.forename: Kazuyoshi
authors.initials: K
authors.lastname: Ishigaki
authors.forename: Oh
authors.initials: O
authors.lastname: Sasaki
authors.forename: Shuji
authors.initials: S
authors.lastname: Sumitomo
authors.forename: Keishi
authors.initials: K
authors.lastname: Fujio
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Yamamoto
mesh_terms: D000328:Adult; D000707:Anaphylaxis / Q000139:chemically induced* / Q000150:complications*; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000276:immunology / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004562:Electrocardiography; D006323:Heart Arrest / Q000175:diagnosis* / Q000209:etiology*; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood; D007074:Immunoglobulin G / Q000097:blood; D000069285:Infliximab; D008297:Male; D013167:Spondylitis, Ankylosing / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D013997:Time Factors; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D014409:Tumor Necrosis Factor-alpha; D007073:Immunoglobulin E; D000069285:Infliximab